NCT06245941View on ClinicalTrials.gov

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

May 31, 2027

Conditions
Myelofibrosis
Interventions
DRUG

TQ05105 tablets

TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor

DRUG

TQB3909 tablets

TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.

Trial Locations (5)

230012

NOT_YET_RECRUITING

The Second People's Hospital of Hefei, Hefei

300122

NOT_YET_RECRUITING

People's Hospital of Tianjin, Tianjin

310003

RECRUITING

The First Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou

450003

NOT_YET_RECRUITING

Hennan Cancer Hospital, Zhengzhou

710032

NOT_YET_RECRUITING

Xijing Hospital of the Fourth Military Medical University, Xi'an

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY